Antisense oligonucleotides targeting C9orf72 hexanucleotide repeat expansion reduce toxic DPR proteins and RNA foci, restoring nuclear TDP-43 localization and splicing function. This is the strongest hypothesis based on genetic prevalence (~40% familial ALS, ~25% FTD), active clinical trial data (NCT04165729), and mechanistic link between repeat transcripts and downstream TDP-43 pathology. Key unresolved questions include the relative contribution of haploinsufficiency vs. gain-of-function and whether TDP-43 inclusions represent a reversible state.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C9orf72 Hexanucleotide G4C2 Repeat Expansion"]
B["Sense + Antisense RNA Foci Formation"]
C["DPR Proteins poly-GR / poly-PR"]
D["Nucleocytoplasmic Transport Impairment"]
E["Proteostasis Failure"]
F["Stress Granule Formation"]
G["Mitochondrial Dysfunction"]
H["Neurodegeneration ALS / FTD"]
A --> B
B --> C
B --> F
C --> D
D --> E
F --> E
E --> G
G --> H
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for C9orf72 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
10 citations10 with PMID5 mediumValidation: 0%8 supporting / 2 opposing
✓For(8)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
5
2
MECH 3CLIN 5GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
ALS-linked mutant TDP-43 in oligodendrocytes induc…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
The C9orf72 hexanucleotide repeat expansion (HRE) drives neurodegeneration through three interconnected gain-of-function pathways that converge on TDP-43 dysfunction:
RNA foci sequestration: Expanded repeat transcripts form nuclear G-quadruplex structures that sequester RNA-binding proteins, including TDP-43 itself, disrupting its normal nuclear function and splicing regulation (PMID: 29198724).
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation
The hypothesis and analysis are well-constructed but rest on assumptions that warrant scrutiny.
Core Weaknesses
1. TDP-43 reversibility remains unestablished. The central therapeutic claim—that pathological TDP-43 inclusions constitute a reversible state—lacks definitive proof. TDP-43 aggregation involves C-terminal fragmentation, hyperphosphorylation, and seeding events that may represent irreversible proteostatic collapse. The theorist conflates reducing further mislocalization with reversing existing inclusions, which are mechanistically distinct.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Translational Assessment: C9orf72 ASO Treatment for ALS/FTD
Druggability & Feasibility
C9orf72 ASOs are among the most translationally advanced genetic interventions in ALS/FTD. Ionis and Biogen's BIIB078 (ION364) has completed Phase 1 testing (NCT04165729), establishing human safety and CSF exposure. ASOs are well-suited to CNS delivery via lumbar intrathecal injection, with established nonclinical packages. The mechanism is genetically validated—C9orf72 HRE accounts for ~40% of familial ALS and ~25% of FTD cases, representing a large, defined patient population with clear bi
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"hypothesis_title":"C9orf72 ASO Treatment Reverses TDP-43 Pathology in ALS/FTD","synthesis_summary":"C9orf72 ASOs represent one of the most translationally advanced genetic therapies for ALS/FTD, with Phase 1 safety established and biomarker readouts enabling target engagement verification. However, the core therapeutic claim of reversing established TDP-43 pathology remains mechanistically unproven, as ASO-mediated reduction of DPR proteins may only prevent further mislocalization rather than dissolve existing inclusions. The hypothesis shows strong druggability and genetic validation but
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF C9orf72 ASOs (IONX-586 or equivalent) are administered to C9-BAC transgenic mice at 8 weeks of age (pre-symptomatic) for 12 weeks at 20 mg/kg via intracerebroventricular infusion, THEN CNS DPR protein levels (poly-GA, poly-GR, poly-PR) will decrease by ≥50% (measured by ELISA) AND nuclear TDP-43 fluorescence intensity will increase by ≥30% in motor neurons (measured by immunohistochemistry), compared to vehicle-treated controls.
pendingconf: 0.72
Expected outcome: ≥50% reduction in cortical/spinal cord DPR aggregates and ≥30% restoration of nuclear TDP-43 immunoreactivity in motor neurons within 12 weeks of treatment onset.
Falsified by: DPR protein levels unchanged or increased AND TDP-43 nuclear/cytoplasmic ratio shows no significant improvement (p>0.05) compared to vehicle, despite confirmed ASO uptake in CNS tissue.
Method: C9-BAC transgenic mice (line 100, Jackson Labs) treated with C9orf72-targeting ASO (sequence: 5'-mC*mU*mG*mC*mA*mG*mC*mU*mG*mC*mU*mC*mA*mC*mC*mC-3', 2'-MOE chemistry) via ICV osmotic pump. Endpoints: DPR ELISA (Millipore), TDP-43 IHC (Proteintech #60019-2-Ig) with confocal quantification. n=12 per group.
IF C9orf72 ASO treatment reduces DPR levels in patient-derived iPSC motor neurons from C9-ALS/FTD subjects, THEN exon 32 splicing of UNC13A (a validated TDP-43 target) will normalize to levels comparable to unaffected controls within 4 weeks of ASO exposure (10 μM, 14 days), with ≥40% restoration of normal splicing pattern.
pendingconf: 0.68
Expected outcome: UNC13A exon 32 inclusion ratio ≥0.75 (normalized to control lines) and restoration of normal neurite length and survival to ≥80% of control values.
Falsified by: UNC13A exon 32 splicing remains dysregulated (>20% deviation from disease baseline) AND neuronal survival shows no improvement despite confirmed DPR reduction (poly-GA ELISA) after ASO treatment.
Method: iPSC-derived motor neurons from 3 C9-ALS subjects (NINDS repository) and 3 CRISPR-corrected isogenic controls. ASO treatment (C9-targeting, 2'-MOE, 10 μM for 14 days). Outcomes: RT-PCR for UNC13A splicing (primers flanking exon 32), poly-GA ELISA (Mblr #2775), neurite length analysis (Neurite Quant). Primary replication in independent iPSC lines.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮
C9ORF72 — AlphaFold Prediction Q96LT7Click to expand 3D viewer
AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click